Understanding FDA Biocompatibility Requirements: A Risk-Based Approach for Medical Device Manufacturers

Biocompatibility is straightforward at its core: your device materials must not cause an unacceptable biological response in the body under their intended use conditions. In practice, that means you need to understand how your device contacts the body, for how long, what biological hazards exist, and how you'll demonstrate that biological risks are acceptable.

What FDA Biocompatibility Requirements Actually Cover

FDA uses biocompatibility evaluation to judge whether your device is biologically safe, not just mechanically or electrically safe. While FDA's current biocompatibility guidance predates the latest ISO 10993-1:2025 standard, the agency expects you to take a risk-based approach grounded in systematic biological risk assessment. You justify your biocompatibility strategy with science and documented risk analysis, not by reflexively following outdated testing matrices.

Why ISO 10993-1:2025 Matters

ISO 10993-1:2025, published in November 2025, is the current international standard for biological evaluation of medical devices and forms the backbone of FDA's expectations. The 2025 edition represents a fundamental shift from the previous matrix-based approach to systematic biological risk assessment.

ISO 10993-1:2025 provides a structured framework to:

Characterize your device including materials, physical characteristics, manufacturing processes, and patient contact scenarios

Identify biological hazards based on device characteristics and intended use

Estimate biological risks using available information from multiple sources

Determine information needs through systematic risk assessment rather than automatic testing requirements

Gather existing information before conducting new testing, including material data, literature, chemical characterization, and history of use

Conduct additional evaluation only when existing information is insufficient to adequately assess biological risks

Provide scientific justification for all decisions, including decisions not to conduct specific tests

This risk-based approach emphasizes animal welfare, efficient use of resources, and scientifically defensible safety conclusions.

Which Devices Need Biocompatibility Assessment

Any device that directly or indirectly contacts the body requires biological evaluation. This includes:

Surface-contacting devices including those contacting intact skin, breached or compromised surfaces, or mucosal membranes

External communicating devices with indirect blood path contact or tissue/bone/dentin communication

Implant devices with contact to tissue, bone, or circulating blood

Even devices with limited, brief contact require systematic biological risk assessment to determine what evaluation is appropriate. The nature, frequency, and duration of contact inform—but do not automatically prescribe—what biological evaluation activities are needed.

For U.S. submissions, your biological evaluation approach drives your testing plan, scientific justification narrative, and how smoothly your 510(k), De Novo, or PMA review proceeds.

The Risk-Based Framework for Biocompatibility Evaluation

Think of FDA's biocompatibility expectations as structured risk management applied to biological safety. ISO 10993-1:2025 provides the framework, and FDA guidance helps you understand how to apply it in regulatory submissions.

Start With Comprehensive Device Characterization

You begin by characterizing the device and its materials in detail. Under ISO 10993-1:2025, this means identifying:

All materials with direct or indirect patient contact, including base materials, additives, processing aids, coatings, colorants, and residues

Physical characteristics including porosity, particle size, shape, surface morphology, and configuration

Manufacturing process impacts such as passivation, laser marking, surface treatments, or cleaning processes that affect biological safety

Sterilization effects including method, parameters, and any residuals or material changes

Packaging interactions where primary packaging materials may transfer constituents to the device

Potential degradation products for devices that intentionally or unintentionally degrade during use

This comprehensive characterization forms the foundation for biological risk assessment.

Identify Biological Hazards and Estimate Risks

Next, you systematically identify biological hazards associated with your device. This involves:

Categorizing patient contact by type (surface, external communicating, implant), location (skin, mucosal membrane, blood, tissue, bone), frequency, and duration (limited ≤24 hours, prolonged >24 hours to 30 days, permanent >30 days)

Identifying potential biological hazards based on materials, chemical constituents, physical characteristics, and intended use

Estimating biological risks using available information including material safety data, literature, similar device experience, and post-market data

Determining information gaps where existing information is insufficient to adequately assess biological risks

This systematic risk assessment—not an endpoint matrix—determines what additional evaluation is needed.

Determine What Information is Needed

Using your biological risk assessment, you determine what information is required to demonstrate biological safety. Options include:

Existing material information from suppliers, literature, or regulatory databases

Chemical characterization to identify and quantify extractables and leachables, followed by toxicological risk assessment

Biological testing where chemical characterization or existing information cannot adequately address biological risks

Clinical data from similar devices or post-market experience

Physical characterization for devices where physical properties (particle size, surface characteristics) drive biological response

The key principle: gather and evaluate existing information before conducting new testing, particularly animal testing.

Key Components of Biocompatibility Evaluation

Once you've determined what information is needed through biological risk assessment, you plan appropriate evaluation activities.

Chemical Characterization and Toxicological Risk Assessment

For many devices, chemical characterization provides the most relevant biological safety information, particularly for systemic biological endpoints.

Extractables and leachables analysis identifies and quantifies chemical constituents that may migrate from the device under clinical use conditions. This involves:

• Selecting appropriate extraction vehicles and conditions based on contact type

• Using validated analytical methods (GC-MS, LC-MS, ICP-MS, etc.)

• Identifying and quantifying detected constituents

• Establishing detection limits appropriate for toxicological assessment

Toxicological risk assessment evaluates the safety of identified constituents by:

• Estimating patient exposure based on constituent levels and clinical use

• Identifying toxicological hazards for each constituent

• Comparing exposure to appropriate toxicological thresholds (TDI, PDE, TTC, NOAEL)

• Calculating margins of safety

• Determining overall biological risk acceptability

Chemical characterization with toxicological risk assessment is particularly effective for addressing systemic biological endpoints (systemic toxicity, genotoxicity, carcinogenicity, reproductive toxicity) and often eliminates the need for animal testing for these endpoints.

Biological Testing When Necessary

Biological testing is conducted when existing information, including chemical characterization, is insufficient to adequately assess biological risks. Common biological tests include:

Cytotoxicity screening for cell damage from device materials or extracts

Sensitization assessing potential for delayed hypersensitivity or allergic responses

Irritation evaluating local inflammatory responses at contact sites

Implantation assessing local tissue response to physically implanted materials over time

Important distinction: Local tissue effects (cytotoxicity, sensitization, irritation, implantation) typically require biological testing even when comprehensive chemical characterization is available, because toxicological databases for local tissue responses are limited and physical device characteristics significantly impact local effects.

Test Article Preparation

When biological testing is conducted, your test article must represent the finished device in its clinical use configuration:

Correct materials matching final device specifications

Final manufacturing processes including all surface treatments and processing steps

Appropriate sterilization using the actual sterilization method and parameters

Realistic aging if shelf life or use duration affects biological response

Worst-case configuration for extraction studies, matching maximum surface area and contact conditions

Avoid "lab special" builds that skip real processing steps, as these don't represent actual patient exposure.

Reconciling FDA Guidance with ISO 10993-1:2025

FDA's current biocompatibility guidance predates ISO 10993-1:2025 and references the old endpoint matrix approach. This creates a practical challenge manufacturers must navigate in 2026.

The Practical Approach

Conduct systematic biological risk assessment as required by ISO 10993-1:2025, identifying biological hazards and determining information needs based on device characteristics and intended use.

Consider FDA's endpoint guidance as input to your risk assessment. FDA's guidance identifies biological effects that have historically been relevant for different contact types and durations.

Provide clear scientific justification for your evaluation approach, explaining how you addressed relevant biological effects through chemical characterization, biological testing, or existing information.

Expect reviewer questions during the transition period as FDA reviewers familiar with the matrix approach adapt to risk-based evaluation. Prepare strong scientific rationales for decisions not to conduct specific tests.

Intact Skin Devices

FDA's Attachment G provides a risk-based framework for intact skin contact devices. Instead of reflex testing, FDA expects you to:

Clarify true contact scenario including realistic misuse and off-label placement possibilities

Use material information and chemistry to argue for reduced or no testing where justified

Document explicitly why additional biological endpoints do or do not add value

This doesn't mean "no testing for skin contact"—it means testing that is justified and proportionate to biological risks.

Preparing and Submitting Biocompatibility Data to FDA

Think of your submission as a coherent story explaining why your device is biologically safe, not a collection of disconnected test reports. FDA wants to see your scientific logic as much as your laboratory data.

What FDA Expects to See

Biological evaluation plan documenting your systematic biological risk assessment, identified hazards, information needs determination, and evaluation strategy with scientific justification for all decisions.

Device and material description including complete material list, manufacturing overview, sterilization method, surface treatments, and any factors affecting patient contact or biological response.

Chemical characterization data where applicable, including extraction study design, analytical methods, identified constituents, quantification, and toxicological risk assessment.

Biological test results where testing was conducted, including complete test reports with protocols, acceptance criteria, results, and interpretation—not just certificates of compliance.

Scientific justification clearly explaining the rationale for your evaluation approach, including decisions not to conduct specific tests when existing information was sufficient.

Risk-based conclusions integrating all information sources into clear biological safety conclusions tied to identified biological hazards and risks.

Using Standards and ASCA Labs

Leverage FDA-recognized consensus standards for test methods and clearly identify them in your submission. When possible, select laboratories participating in the ASCA (Accreditation Scheme for Conformity Assessment) program.

Verify laboratory scope covers the specific biocompatibility standards you need (ISO 10993 parts).

Request complete reports that explicitly state standard conformance, include detailed test article descriptions matching your finished device, and provide clear conclusions for each biological endpoint evaluated.

Presenting Results for Smooth Review

Create a concise biocompatibility summary including:

Summary table showing biological effects considered, evaluation approach (existing information, chemical characterization, biological testing), standards or methods used, and conclusions.

Narrative integration connecting device characteristics to biological hazards to evaluation activities to safety conclusions in a logical flow.

Transparent discussion of any borderline results, deviations, or unexpected findings with clear explanation of mitigation or why results remain acceptable.

This organized, scientifically justified presentation facilitates efficient FDA review and reduces deficiency questions.

Bottom Line

FDA biocompatibility requirements in 2026 center on systematic biological risk assessment as defined in ISO 10993-1:2025, not reflexive application of outdated testing matrices. Success requires comprehensive device characterization, identification of biological hazards, strategic use of chemical characterization and toxicological risk assessment, and clear scientific justification for all evaluation decisions.

Manufacturers who embrace ISO 10993-1:2025's risk-based framework—gathering existing information before conducting new testing, using chemical characterization strategically for systemic endpoints, and providing transparent scientific rationale—will find more efficient paths to demonstrating biological safety while meeting FDA expectations.

Expert Biocompatibility Strategy for FDA Submissions

Successfully navigating FDA biocompatibility requirements under ISO 10993-1:2025's risk-based framework requires specialized toxicological expertise and deep understanding of both the standard and regulatory expectations.

At JL Tox Consulting, we help medical device manufacturers develop scientifically defensible biocompatibility strategies that satisfy FDA requirements efficiently.

Our FDA biocompatibility services include:

• Biological evaluation planning using ISO 10993-1:2025 risk-based frameworks

• Chemical characterization strategy and toxicological risk assessment per ISO 10993-18 and ISO 10993-17

• Scientific justification documentation for testing decisions and evaluation approaches

• Biological evaluation report preparation integrating all information sources

• FDA submission support for 510(k), PMA, and De Novo applications

• Deficiency response preparation addressing FDA biocompatibility questions

Contact JL Tox Consulting for expert biocompatibility guidance:

Email: info@JLTox.com

Phone: (877) 899-6568